ANZCTR search results

The primary outcome of this study is to examine whether there is an observable reduction in post operative opioid analgesia required in patients who received a fascia iliaca block in the emergency department for their fractured neck of femur, compared to patients who did not. Secondary outcomes of this study will examine whether a discernible difference between rates of infection and thromboembolic complications exists between these groups of patients.

Patients who require the creation of a new arteriovenous fistula for future haemodialysis will be recruited for this study. They will have a 50/50 chance of being assigned to receive either a brachial plexus block or a general anaesthetic technique for this operation. The main aim of this small trial is to determine if it will be feasible to perform a future larger trial comparing the effects of these two techniques on arteriovenous fistula patency. Therefore, the dual key outcomes for this trial are the proportion of eligible patients successfully recruited and the ability to complete the desired data collection for all recruited patients.

The aim of this clinical trial is to find out whether combination treatment with nivolumab and entinostat is safe and effective for children and adolescents with high-risk cancer. Who is it for? You may be eligible for this study if you are aged 2-21 years old and have been diagnosed with a relapsed or refractory high-risk cancer or high grade glioma with a repair defect of the genetic material. Study details: If you are eligible to participate, you will always receive the drugs nivolumab and entinostat in combination. There will be no placebo or control group with any other medication. Before treatment starts, there will be a screening phase. Molecular profiling (DNA sequencing of the tumour) will be performed and the molecular results will indicate if you are eligible for this study. You will be allocated to one of three biomarker groups and continue with screening. Routine tests will also be performed to confirm whether you are eligible for this study, and if you can start treatment. These include medical history, physical exam, CT or MRI scans of the tumour, ECG, blood tests and urine tests. During study treatment: Entinostat is a tablet or liquid taken once a week. Nivolumab is given at the hospital every two weeks, as an intravenous drip over 30 minutes. Routine tests will be performed during treatment to monitor your health. These include medical history, physical exam, CT or MRI scans of the tumour, ECG, blood tests and urine tests. Additional blood samples are collected for this study to measure the levels of drugs and examine how they are working the body. You will be in this study for up to 4 years. This includes the screening phase, study treatment (12 cycles for about 1 year), follow-up visits (every 4 weeks up to 100 days) and long term observation (every 3 months until the study closes).

This study evaluates the addition of three components (music distraction, distraction via gaming and reappraisal) designed to augment Graduated Extinction for infant sleep problems. Participants will be parents of infants with pediatric insomnia. They will be randomized into 4 groups: (1) Control group, receiving Graduated Extinction alone; (2) Music distraction group receiving Graduated Extinction with a music distraction technique; (3) Distraction via gaming group, receiving Graduated Extinction with a gaming distraction technique; and (4) Reappraisal group receiving Graduated Extinction with a reappraisal technique. Infant sleep and maternal sleep and compliance will be assessed at baseline, and 1- and 6-weeks later. Parental cry tolerance, driving performance, sleepiness and fatigue will also be assessed at these 3 time points.

Plantar heel pain, which is often called Plantar Fasciitis, is a common cause of pain and disability. The condition appears to include the proliferation of blood vessels and nerves in the foot which contribute to the experience of pain. The primary aim of the current study is to determine whether transcatheter arterial embolisation of abnormal neovasculature about the foot improves pain, and specifically if adding an anti-inflammatory medication prior to embolisation affects pain differently than embolisation alone. Secondary aims include whether the treatments affect physical function and quality of life. The study is a randomised trial. People are eligible if they have plantar foot pain that has not responded to other forms of traditional management such as medications, podiatry or physiotherapy. Participants will be randomly allocated to one of two groups. Participants in one group will receive embolisation of abnormal vessels about the foot. Participants in the second group group will receive embolisation and an anti-inflammatory medication that is injected in the blood vessels in the foot. All participants will be assessed shortly before the intervention and then 1, 6 and 12 months after the intervention. Assessment includes a variety of questionnaires and physical tests.

This study aims to assess the cardiovascular risk in people with gout, through performing scanning the heart, and then performing the scan in 6 months. We will determine the impact of having an acute flare of gout on the scans, which is a surrogate of cardiovascular risk. This will help us understand the effect of acute inflammation on cardiovascular risk in gout,

This research project is being conducted to look at the safety, tolerability and pharmacokinetics (PK, how the human body processes a substance) of iCo-019 (oral Amphotericin B when given to healthy volunteers as multiple oral doses for to 10 consecutive days.

In this study we aim to collect dental, saliva, blood and stool samples to characterise the gut microbiome profile of individuals with cardiovascular disease, specifically heart failure patients which include those requiring placement of a ventricular assist device or a heart transplant and compare their microbiome profile to that of healthy individuals. Individuals with cardiovascular disease will have an alteration in the composition and functionality of their gut microbiome compared to healthy individuals.

We are doing a research project to evaluate the Virtual Clinical Pharmacy Service (VCPS) that is being delivered to 8 hospitals in Western and Far West NSW Local Health Districts via a video link. The aim of the virtual pharmacy is to improve medication management, reduce medication harm, help patients manage their medications, and support staff with patients. Routine data collection from patients' electronic medical record will identify if medication management improves, medication harms such as falls are reduced and if people are less likely to be readmitted to hospital compared to those who do not see a pharmacist.

This research project is being conducted to look at the safety, tolerability, pharmacokinetics (PK, how the human body processes a substance) and pharmacodynamics (PD, how the human body interacts with a substance) of SIR1-365 when given to healthy volunteers as a single oral dose or as multiple oral doses for up to 10 consecutive days.